Outlook on the Worldwide Oral Biologics & Biosimilars Industry to 2030 - Featuring Novartis, Rani Therapeutics & Eli Lilly and Co Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Oral Biologics & Biosimilars Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering.

The global oral biologics & biosimilars market was worth $1.15 billion in 2019.

The oral biologics and biosimilar market covered in this report is segmented by therapy into lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors. It is also segmented by disease into asthma, crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others.

Oral Biologics & Biosimilars Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.

Stringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars.

The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market.

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers.

Key Topics Covered:

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Size And Growth

3.1. Global Oral Biologics & Biosimilars Market Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Oral Biologics & Biosimilars Market Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Oral Biologics & Biosimilars Market Segmentation

4.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Oral Biologics & Biosimilars Market Regional And Country Analysis

5.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

  • Novartis
  • Rani Therapeutics
  • Eli Lilly and Co.
  • AstraZeneca plc
  • Novo Nordisk A/S
  • Biocon Limited
  • Oramed Pharmaceuticals
  • BiosanaPharma
  • Entera Bio Ltd.
  • Allergan plc
  • Emisphere Technologies
  • Enteris BioPharma
  • Chiasma
  • Allena Pharmaceuticals
  • Gelgen
  • Ganlee
  • 3sbio
  • Innovent
  • Retractable Technologies, Inc.
  • Changchun High Tech
  • Dong Bao
  • CP Guojian
  • GlaxoSmithKline Plc.
  • Concord Biotech
  • Aurobindo Pharma Ltd.
  • H. Lundbeck A/S
  • Sanofi-Aventis
  • Roche

For more information about this report visit https://www.researchandmarkets.com/r/iwjioj

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900